Logo image of BBLN

BABYLON HOLDINGS LTD- CL A (BBLN) Stock Fundamental Analysis

NYSE:BBLN - New York Stock Exchange, Inc. - JE00BQWMWC12 - Common Stock - Currency: USD

0.5504  -0.09 (-13.99%)

After market: 0.5598 +0.01 (+1.71%)

Fundamental Rating

2

Taking everything into account, BBLN scores 2 out of 10 in our fundamental rating. BBLN was compared to 37 industry peers in the Health Care Technology industry. BBLN may be in some trouble as it scores bad on both profitability and health. BBLN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BBLN has reported negative net income.
BBLN had a negative operating cash flow in the past year.
BBLN Yearly Net Income VS EBIT VS OCF VS FCFBBLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -100M -200M -300M

1.2 Ratios

The profitability ratios for BBLN are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBLN Yearly ROA, ROE, ROICBBLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -100 -200 -300 -400

1.3 Margins

BBLN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBLN Yearly Profit, Operating, Gross MarginsBBLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -200 -400 -600 -800 -1K

More info and screens

1

2. Health

2.1 Basic Checks

BBLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BBLN has more shares outstanding
BBLN has a worse debt/assets ratio than last year.
BBLN Yearly Shares OutstandingBBLN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 20M 40M 60M 80M
BBLN Yearly Total Debt VS Total AssetsBBLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -4.90, we must say that BBLN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.90, BBLN is doing worse than 79.07% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.9
ROIC/WACCN/A
WACC4.64%
BBLN Yearly LT Debt VS Equity VS FCFBBLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 200M -200M

2.3 Liquidity

A Current Ratio of 1.07 indicates that BBLN should not have too much problems paying its short term obligations.
BBLN has a worse Current ratio (1.07) than 62.79% of its industry peers.
A Quick Ratio of 1.07 indicates that BBLN should not have too much problems paying its short term obligations.
BBLN's Quick ratio of 1.07 is on the low side compared to the rest of the industry. BBLN is outperformed by 62.79% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 1.07
BBLN Yearly Current Assets VS Current LiabilitesBBLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

BBLN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -112.81%.
The Revenue has grown by 149.85% in the past year. This is a very strong growth!
Measured over the past years, BBLN shows a very strong growth in Revenue. The Revenue has been growing by 310.57% on average per year.
EPS 1Y (TTM)-112.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.52%
Revenue 1Y (TTM)149.85%
Revenue growth 3Y310.57%
Revenue growth 5YN/A
Sales Q2Q%16.77%

3.2 Future

Based on estimates for the next years, BBLN will show a very strong growth in Earnings Per Share. The EPS will grow by 21.15% on average per year.
BBLN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.34% yearly.
EPS Next Y57.13%
EPS Next 2Y32.22%
EPS Next 3Y21.15%
EPS Next 5YN/A
Revenue Next Year11.12%
Revenue Next 2Y9.08%
Revenue Next 3Y14.59%
Revenue Next 5Y31.34%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BBLN Yearly Revenue VS EstimatesBBLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 1B 2B 3B
BBLN Yearly EPS VS EstimatesBBLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BBLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BBLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBLN Price Earnings VS Forward Price EarningsBBLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBLN Per share dataBBLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

A more expensive valuation may be justified as BBLN's earnings are expected to grow with 21.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.22%
EPS Next 3Y21.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BBLN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BABYLON HOLDINGS LTD- CL A

NYSE:BBLN (6/28/2023, 8:04:01 PM)

After market: 0.5598 +0.01 (+1.71%)

0.5504

-0.09 (-13.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)05-10 2023-05-10/bmo
Earnings (Next)08-07 2023-08-07/amc
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners13.22%
Ins Owner Change0%
Market Cap14.08M
Analysts40
Price Target7.65 (1289.9%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.99%
Min EPS beat(2)0.13%
Max EPS beat(2)9.85%
EPS beat(4)3
Avg EPS beat(4)2.78%
Min EPS beat(4)-1.28%
Max EPS beat(4)9.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)132.53%
Min Revenue beat(2)-9.58%
Max Revenue beat(2)274.65%
Revenue beat(4)2
Avg Revenue beat(4)66.81%
Min Revenue beat(4)-9.58%
Max Revenue beat(4)274.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-42.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.48%
EPS NY rev (1m)0%
EPS NY rev (3m)35.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-14.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-18.28
EYN/A
EPS(NY)-5.54
Fwd EYN/A
FCF(TTM)-13.24
FCFYN/A
OCF(TTM)-13.36
OCFYN/A
SpS77.2
BVpS-12.31
TBVpS-12.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover9.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 1.07
Altman-Z -4.9
F-Score3
WACC4.64%
ROIC/WACCN/A
Cap/Depr(3y)358.28%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.52%
EPS Next Y57.13%
EPS Next 2Y32.22%
EPS Next 3Y21.15%
EPS Next 5YN/A
Revenue 1Y (TTM)149.85%
Revenue growth 3Y310.57%
Revenue growth 5YN/A
Sales Q2Q%16.77%
Revenue Next Year11.12%
Revenue Next 2Y9.08%
Revenue Next 3Y14.59%
Revenue Next 5Y31.34%
EBIT growth 1Y4.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.12%
EBIT Next 3Y26.85%
EBIT Next 5Y20.95%
FCF growth 1Y-72.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.58%
OCF growth 3YN/A
OCF growth 5YN/A